Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy on OCT

AI Generated Summary*

Post hoc analysis of the 24-month phase 3 OAKS and DERBY trials applied deep learning segmentation to 11,614 spectral-domain OCT volumes from 936 participants with geographic atrophy secondary to age-related macular degeneration. Compared with pooled sham, pegcetacoplan monthly or every other month was associated with slower growth of RPE and outer retinal atrophy at month 24 (differences of 0.86 and 0.69 mm2, both P<.001); monthly dosing also showed smaller increases in RPE loss, hypertransmission and photoreceptor degeneration, while isolated photoreceptor degeneration declined in both treated arms and rose under sham through month 18. Differences were clearer parafoveally and perifoveally; foveal findings were minimal, possibly because 96% of eyes already had foveal-region atrophy at baseline. No visual acuity benefit emerged.

*This summary was generated by AI and is published unedited. Oku does not alter these summaries. It may contain errors or omissions and is provided for general informational purposes only. Oku does not guarantee its accuracy, completeness, or reliability. For authoritative information, please refer to the original, peer-reviewed article.